Additionally, CC-90009 has entered clinical trials for the treatment of patients with acute myeloid leukaemia [14,18], which lays the groundwork for the application of GSPT1-deletion-based strategies in treating viral infections. Here, GSPT1 is linked to viral infectious disease.